financetom
Business
financetom
/
Business
/
Sony Buys Amber's Japan Unit to Enter the Crypto Market: Reports
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Sony Buys Amber's Japan Unit to Enter the Crypto Market: Reports
Jul 1, 2024 12:38 AM

The terms of the deal were undisclosed.Last year, Bloomberg had reported that Amber was planning to sell its Japanese unit.Japan-based technology giant Sony Group ( SONY ) has bought crypto exchange Amber Japan in a bid to enter the crypto market, according to multiple crypto media reports.

Wu Blockchain initially reported the deal, which was later substantiated by the Block.

Exclusive: Sony Group ( SONY ), one of Japan's largest companies, has acquired Amber Japan, officially entering the crypto exchange field. Sony's ( SONY ) businesses include games, music, cameras, etc., with a market value of more than $100 billion. Singapore market maker Amber Group acquired… pic.twitter.com/XOHFIUmKtJ

-- Wu Blockchain (@WuBlockchain) July 1, 2024The terms of the deal were undisclosed.

While Sony ( SONY ) has dabbled in Web 3 through investments and partnerships, the latest deal will mark the PlayStation maker's proper foray into crypto. The company had teamed up with the Astar Network for a Web3 incubation program and filed a patent for transferring non-fungible tokens (NFTs) between different games and consoles.

Amber Japan, formerly known as DeCurret, was taken over by crypto finance firm Amber Group in 2022 and subsquently renamed. Amber had bought DeCurret through its local unit, WhaleFin Holdings Japan.

Sony ( SONY ) and Amber were not immediately available for comment.

Last year, Bloomberg reported that the Hong Kong-based Amber Group was planning to sell its Japan unit due to the strict regulations in the nation.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
Verve Therapeutics pauses enrollment in early-stage gene therapy study for high cholesterol levels
Apr 2, 2024
April 2 (Reuters) - Verve Therapeutics ( VERV ) said on Tuesday that it had paused enrollment for an early-stage study testing its experimental gene editing therapy for high cholesterol after a patient experienced a severe drug-related adverse event. The company was testing the therapy in patients with a genetic condition that leads to high cholesterol levels, which raises the...
BRIEF-Accenture To Acquire Intellera Consulting
BRIEF-Accenture To Acquire Intellera Consulting
Apr 2, 2024
April 2 (Reuters) - Accenture PLC ( ACN ): * ACCENTURE TO ENHANCE DIGITAL TRANSFORMATION CAPABILITIES FOR ITALY'S PUBLIC SECTOR WITH ACQUISITION OF INTELLERA CONSULTING * ACCENTURE PLC ( ACN ): HAS AGREED TO ACQUIRE INTELLERA CONSULTING Source text for Eikon: Further company coverage: ...
Amazon offers free credits for startups to use AI models including Anthropic
Amazon offers free credits for startups to use AI models including Anthropic
Apr 2, 2024
(Reuters) - Amazon Web Service (AWS) has expanded its free credits program for startups to cover the costs of using major AI models, the company told Reuters in an interview, as it looks to boost the market share of its AI platform Bedrock. In a move to attract startup customers, Amazon ( AMZN ) now allows its cloud credits to...
Roivant's anti-inflammatory drug succeeds in mid-stage study
Roivant's anti-inflammatory drug succeeds in mid-stage study
Apr 2, 2024
By Bhanvi Satija April 2 (Reuters) - Roivant Sciences ( ROIV ) said on Tuesday its experimental drug to treat non-infectious uveitis helped reduce symptoms of the inflammatory eye disease in a mid-stage study. In the study testing 26 patients, 29% of those who received a higher-strength 45 milligram (mg) dose and 44% of those who received a 15 mg...
Copyright 2023-2026 - www.financetom.com All Rights Reserved